PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma.
The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization.
METHODS: Using administrative data...
Full Text:
FDA’s 2010 Drug
Safety Communication
Hartung, D. M., Middleton, L., Markwardt, S., Williamson, K
PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma.
The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization.
METHODS: Using administrative data...
PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma.
The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization.
METHODS: Using administrative data...
PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma.
The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization.
METHODS: Using administrative data...
PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma.
The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization.
METHODS: Using administrative data...
PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma. The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization. METHODS: Using administrative data...